PI3K or ERK inhibitors have been suggested as anti-inflammatory agents acting by blocking neutrophil recruitment or promoting resolution of inflammation.53, 54 JAK inhibitors already have a role in combatting myeloproliferative disease and immunological disorders.55, 56, 57 Part of the therapeutic effect of these inhibitors is possibly due to inhibition of A1 and/or Mcl-1 activity. The gene discussed is MCL1; the disease is myeloproliferative disorder.